Applied dna submits validation package to new york state department of health for h5 bird flu/pan-influenza a laboratory-developed test

Stony brook, ny / access newswire / march 26, 2025 / applied dna sciences, inc. (nasdaq:apdn) (applied dna or the "company"), a leader in pcr-based dna technologies, today announced that applied dna clinical labs (adcl), the company's wholly-owned clinical laboratory subsidiary, has submitted a validation package to the new york state department of health (nysdoh) to request approval as a laboratory-developed test (ldt) for a pcr-based assay for the detection and subtyping of influenza a (h5) virus, also known as h5 bird flu, highly pathogenic avian influenza, or h5n1 (collectively "h5 bird flu"). adcl's linea™ avian influenza h5 dx assay ("aih5 dx") is a highly sensitive, multi-target diagnostic assay capable of detecting and discriminating between pan-influenza a and h5 bird flu.
APDN Ratings Summary
APDN Quant Ranking